Abstract 77P
Background
Neuroblastoma (NBL) is the most common and aggressive cancer in infants, and there are no robust predictive nomograms for NBL. In this study, a database from the Therapeutically Applicable Research to Generate Effective Treatments was applied to develop and validate a prognostic nomogram for the prediction of individual 5-year overall survival (OS) probability in patients with NBL.
Methods
A total of 729 eligible NBL patients with their clinicopathological factors and biological characteristics from the database were assigned to either the training cohort (n = 511) or the validation cohort (n = 218). Independent predictors were identified by fitting the Cox model with lasso penalty and then were assembled into a nomogram to predict survival. The model was developed for predicting individual 5-year OS probability and was then internally and externally validated, calibrated and compared in each cohort.
Results
Four independent prognostic factors (International NBL Staging System stage, ploidy, histology and Children’s Oncology Group risk group) were discriminated and achieved favourable prediction efficacy following the lasso model. The prognostic nomogram incorporated those factors that performed well in the training and validation cohorts with OS (HR = 0.36, 95% CI: 0.27-0.48, P < 0.0 001; HR = 0.54, 95% CI: 0.34-0.86, P = 0.0 086; respectively) and recurrence-free survival (HR = 0.52, 95% CI: 0.40-0.67, P < 0.0 001; HR = 0.66, 95% CI: 0.44-0.99, P = 0.044; respectively).
Conclusions
The robust prognostic nomogram with four independent prognostic factors can accurately and diversely predict OS and recurrence-free survival in NBL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract
97P - The role of adjuvant chemotherapy according to the status of surgical margin in rectal cancer
Presenter: Jong Hoon Lee
Session: Poster display session
Resources:
Abstract